Frazier Life Sciences Management L.P. Has $329.90 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Frazier Life Sciences Management L.P. increased its stake in **NewAmsterdam Pharma** by 1.3%, now holding approximately **16.1 million shares**, which represent **15.1%** of its investment portfolio.
• Multiple institutional investors have boosted their positions, with **Deerfield Management** increasing its holdings by **378.4%** in the latest quarter, now owning over **4.3 million shares**.
• NewAmsterdam Pharma reported a **loss per share of ($0.15)** for the last quarter, exceeding analysts' expectations, and achieved revenue of **$19.15 million**, well above the **$1.44 million** forecast.

Frazier Life Sciences Management L.P. boosted its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 1.3% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 16,116,418 shares of the company's stock after buying an additional 200,000 shares during the period. NewAmsterdam Pharma accounts for approximately 15.1% of Frazier Life Sciences Management L.P.'s holdings, making the stock its biggest position. Frazier Life Sciences Management L.P. owned about 14.68% of NewAmsterdam Pharma worth $329,903,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Maverick Capital Ltd. increased its stake in shares of NewAmsterdam Pharma by 57.0% during the first quarter. Maverick Capital Ltd. now owns 549,469 shares of the company's stock worth $11,248,000 after purchasing an additional 199,464 shares in the last quarter. Caption Management LLC grew its position in NewAmsterdam Pharma by 341.3% during the 1st quarter. Caption Management LLC now owns 30,934 shares of the company's stock worth $633,000 after purchasing an additional 43,756 shares during the last quarter. Quarry LP acquired a new stake in shares of NewAmsterdam Pharma in the first quarter valued at about $25,000. Trexquant Investment LP acquired a new position in NewAmsterdam Pharma during the first quarter worth about $1,353,000. Finally, OMERS ADMINISTRATION Corp grew its holdings in NewAmsterdam Pharma by 83.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 37,700 shares of the company's stock valued at $772,000 after purchasing an additional 17,200 shares during the period. Institutional investors own 89.89% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on NAMS shares. Citigroup started coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price for the company. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a "buy" rating and a $44.00 price target for the company. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a research note on Monday, August 25th. They issued an "overweight" rating and a $45.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $41.55.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded up $1.34 during mid-day trading on Friday, reaching $27.00. The company had a trading volume of 1,570,503 shares, compared to its average volume of 806,032. The company has a market capitalization of $3.04 billion, a P/E ratio of -16.67 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29. The stock's 50-day simple moving average is $22.98 and its 200-day simple moving average is $20.56.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.37. The business had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. On average, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Insider Activity

In related news, COO Douglas F. Kling sold 100,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $19.29, for a total value of $1,929,000.00. Following the transaction, the chief operating officer directly owned 44,000 shares of the company's stock, valued at approximately $848,760. The trade was a 69.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the firm's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the completion of the sale, the insider owned 119,302 shares in the company, valued at $2,897,845.58. This represents a 29.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 12,835 shares of company stock worth $248,134 and have sold 274,954 shares worth $5,899,406. 20.84% of the stock is currently owned by insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.